
|Articles|January 1, 2006
- Volume 0 0
Hydase (hyaluronidase injection, USP)
Advertisement
PrimaPharm Inc (San Diego, Calif) recently received FDA approval for a new drug application for Hydase 150 units/mL for use as a spreading agent to facilitate the dispersion and absorption of other drugs. Hydase is also indicated for hypodermoclysis and as an adjunct in the subcutaneous urography for improving resorption of radiopaque agents. The product is supplied sterile as 150 USP units of hyaluronidase per mL in a 2-mL nonpreserved, single-use glass vial. For more information, call 866-339-6589, or visit
Articles in this issue
over 20 years ago
Resealable and Nultraviolet Ultraviolet (UV) Inhibitant Bagsover 20 years ago
High Alert Insulin Binover 20 years ago
Humira (adalimumab)over 20 years ago
INVANZ (ertapenem for injection)over 20 years ago
Compounding HOTLINEover 20 years ago
Customer Guilty of Prescription Fraud by Supporting Friendover 20 years ago
Counterfeit Drugs: A Life-or-Death Problemover 20 years ago
Qui Tam Lawsuits Blow the Whistle on PBMsover 20 years ago
Can You Read These Rxs?over 20 years ago
What You Need to Know About Alzheimer's DiseaseAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Q&A: Pharmacy Technicians and the Future of Obesity Management
2
How Advanced Technology Is Reshaping Medication Safety and Pharmacy Practice
3
GLP-1 Receptor Agonists Linked to Improved Survival Outcomes in Breast Cancer
4
Single Dose of Psilocybin Demonstrates Rapid Relief of Depression Symptoms in Phase 2 Trial
5



































































































































